Cannabis Law Report

MAY 31, 2022

The only psychedelic drug that is approved (outside of clinical trials) for psychiatric use—as opposed to anesthesia—through the traditional medical system is Ketamine. Food and Drug Administration (FDA) approved esketamine (a component of Ketamine and sold under the brand name Spravato) for treatment-resistant depression.

Clinical Trials 52

Clinical Trials Legalization Therapy Decriminalization 52

SpeedWeed

MAY 22, 2021

The US Food and Drug Administration (FDA) has just approved a new clinical trial that will allow therapists to legally use MDMA. For this Phase 1 trial, MAPS will recruit 150 therapists that are currently being trained to conduct MDMA-assisted therapy sessions for PTSD. .

Clinical Trials 52

Clinical Trials Therapy Legalization Research and Development 52

Cannabis Law Report

SEPTEMBER 23, 2022

Bronner’s, Law Enforcement Action Partnership (LEAP), New Approach, Heroic Hearts Project, Sacred Garden Community, the Indigenous Peyote Conservation Initiative (IPCI), Veterans Exploring Treatment Solutions (VETS), and local organizations and advocates.

Decriminalization 52

Decriminalization Advocacy Research and Development Clinical Trials 52

Cannabis Law Report

MAY 12, 2022

Lophora has previously secured grant funding from the BioInovation Institute (Novo Nordisk Foundation) and continues to characterise its lead candidates, aiming to initiate clinical trials in 2023. Lophora expects LPH-5 to be IND ready in Q4 2022 and plans to begin first-in-human trials in 2023.

Medicine 52

Medicine Research and Development Clinical Trials Treatment 52

Cannabis Law Report

OCTOBER 4, 2021

A multitude of recent clinical trials shows the clear promise of psilocybin for this population suffering from these debilitating conditions. Accordingly, it cannot be prescribed by a physician and it is not legally accessible to those who might benefit from it as a therapeutic treatment.

Therapy 52

Therapy Patients Law Clinical Trials 52

The Joint Blog

JANUARY 12, 2020

billion by 2023, according to the cannabis research firm Brightfield Group and noted by the AP. This year, it has sent warning letters to 22 companies citing violations such as making claims about therapeutic uses and treatment of disease in humans or animals or marketing CBD as a dietary supplement or food ingredient.

Pets 36

Pets CBD Clinical Trials Research and Development 36

Cannabis Law Report

DECEMBER 2, 2021

Recommendations and rulemaking relating to training and products were placed on an expedited timeline to ensure that facilitators will be trained, and products will be ready for the January 2, 2023, launch of the first state-sponsored psilocybin therapy program in the United States. Group Psilocybin Facilitation (8 Hours).

Law 52

Law Programs Therapy Education 52

Project CBD

FEBRUARY 27, 2023

In the absence of an answer — or a cure — treatment is the name of the game for fibromyalgia. “Available data strongly support the use of cannabinoids in treating fibromyalgia pain” due to “overwhelmingly positive treatment results.” It’s not a new idea. That seemed to make all the difference.

THC 144

THC CBD Clinical Trials Sleep 144

Cannabis Law Report

DECEMBER 21, 2021

billion in 2023. Ignite products are ecologically responsible and do not require additional wastewater treatment. Payal Keswarpu, presented cerVIA™ clinical study results at the 17th World Congress for Cervical Pathology and Colposcopy before 42 participating countries. billion (2020).

Research and Development 40

Research and Development Supply Chain Data Business 40

Project CBD

MARCH 21, 2023

Auditory & Other Symptoms The survey, whose findings were published in February 2023 in the Journal of Otolaryngology – Head & Neck Surgery 1 evaluated cannabis perceptions and consumption among 45 adult tinnitus patients randomly selected and recruited from an outpatient ear, nose, and throat clinic in Ontario, Canada.

Cannabinoids 144

Cannabinoids Clinical Trials Sleep Blood Pressure 144

Cannabis Law Report

AUGUST 18, 2022

Smith , a partner with the firm and co-leader of the firm’s Life Sciences & Health Effects Team, will lead the practice, bringing together scientist-attorneys and experienced litigators to support clients that are driving innovation in mental health treatments. Tweet this. However, change appears imminent. ” Joining Ms.

Therapy 52

Therapy Research and Development Pharmaceutical Treatment 52

Cannabis Law Report

MAY 29, 2022

Widespread approval for psychedelic treatments remains unlikely, but the tide is slowly turning. In 2019, FDA approved Spravato (esketamine) nasal spray for treatment of depression in adults. [8] 9] Experts predict that this therapy could receive full FDA approval as soon as 2023. [10] Defining Psychedelics. Challenges.

Research and Development 52

Research and Development DEA Clinical Trials Therapy 52

Cannabis Law Report

DECEMBER 21, 2021

This UK-based company caught our attention in 2021 for its team of renowned psychedelic researchers, including chief research officer Professor David Nutt, chief medical officer Dr. Ben Sessa, and head of ketamine psychotherapy Dr. Celia Morgan, as well as its unique studies into ketamine treatment for addiction and gambling addiction.

Clinical Trials 52

Clinical Trials Therapy Treatment DEA 52

Cannabis Law Report

JUNE 14, 2022

Ketamine is already registered for the treatment of depression and in 2023, the FDA might approve an MDMA assisted therapy for PTSD. There are multiple clinical centers doing research with psychedelics in Europe and, inevitably, regulatory approvals in Europe will follow.

Access 52

Access Therapy Clinical Trials Treatment 52

Cannabis Law Report

JULY 29, 2022

The duo filed separate amendments on expanding psychedelics research to service members that earlier this month got attached to the fiscal 2023 National Defense Authorization Act ( H.R. The trials would study treatments with psilocybin, MDMA, and ibogaine — a naturally occurring psychoactive substance — Crenshaw said.

Clinical Trials 52

Clinical Trials Treatment Legislation Programs 52